TNXP Tonix Pharmaceuticals Holding Corp

Tonix Pharmaceuticals to Participate in BIO Investor Forum Digital

Tonix Pharmaceuticals to Participate in BIO Investor Forum Digital
EN
07/10/2020

Underlying

TNXPTonix Pharmaceuticals Holding Corp

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Tonix Pharmaceuticals Holding Corp

 PRESS RELEASE
Free
TNXP Tonix Pharmaceu...

Tonix Pharmaceuticals Announces Peer-Reviewed Publication in Cancer Ce...

Tonix Pharmaceuticals Announces Peer-Reviewed Publication in Cancer Cell Journal Highlighting Positive Preclinical Data of mTNX-1700 in Gastric Cancer Animal Models Combination treatment of mTNX-1700 (mTFF2-MSA fusion protein) with anti-PD1 antibody was associated with increased survival and decreased metastases in animal models of gastric cancer relative to anti-PD1 treatment alone mTNX-1700 treatment was associated with activation of cancer-killing CD8+ T Cells and limiting neutrophil-mediated immune evasion TNX-1700 (hTFF2-HSA fusion protein) is in preclinical development for gastr...

July 2, 2025 1 EN
 PRESS RELEASE
Free
TNXP Tonix Pharmaceu...

Tonix Pharmaceuticals Announces Inclusion in the Russell 3000® and Rus...

Tonix Pharmaceuticals Announces Inclusion in the Russell 3000® and Russell 2000® Indexes CHATHAM, N.J., June 30, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biotechnology company, today announced that it will be added to the broad-market Russell 3000® Index, with automatic inclusion in the small-cap Russell 2000® Index, after the open of U.S. equity markets today, June 30, 2025, as part of the 2025 Russell indexes reconstitution. The annual reconstitution of the Russell US indexes captures the 4,000 largest US sto...

June 30, 2025 1 EN
 PRESS RELEASE
Free
TNXP Tonix Pharmaceu...

Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatm...

Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the Annual European Congress of Rheumatology (EULAR) 2025 TNX-102 SL is a sublingual formulation of cyclobenzaprine designed for transmucosal delivery and durable activity in treating fibromyalgia: FDA PDUFA goal date of August 15, 2025 TNX-102 SL demonstrated statistically significant improvement in the primary endpoint of reduction in fibromyalgia pain in two double-blind randomized placebo-controlled Phase 3 studies If approved by FDA, TNX-102 SL would become the first member of a new c...

June 16, 2025 1 EN
 PRESS RELEASE
Free
TNXP Tonix Pharmaceu...

Tonix Pharmaceuticals Announces Appointment of Commercial Industry Vet...

Tonix Pharmaceuticals Announces Appointment of Commercial Industry Veteran, James “Jim” Hunter, to Board of Directors Mr. Hunter brings more than 40 years of experience building and leading commercial organizations in the biopharmaceutical industry, including leadership roles at Validus Pharmaceuticals, Relialab and Novartis Led launch of Tonix Medicines, acquisition of migraine assets Zembrace® SymTouch® and Tosymra®, and recruitment of commercial leadership team Appointment strengthens commercial strategy and governance as Tonix prepares for potential launch of TNX-102 SL for fibromyalg...

June 13, 2025 1 EN
 PRESS RELEASE
Free
TNXP Tonix Pharmaceu...

Tonix Pharmaceuticals Announces Presentation at the 2025 BIO Internati...

Tonix Pharmaceuticals Announces Presentation at the 2025 BIO International Convention CHATHAM, N.J., June 10, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biotechnology company with marketed products and a pipeline of development candidates, today announced that Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, will present at the 2025 BIO International Convention, being held June 16-19, 2025, in Boston, Mass. The Company’s presentation will take place on Monday, June 16, at 5:00 p.m. in Room 15...

June 10, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch